Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TdCyd in Advanced Solid Tumors
NCT02423057Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- May 2015
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 4-thio-2-deoxycytidine in solid tumor, sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 3 weeks and Safety and Tolerability at 3 weeks. Started May 2015; status: completed.
02
Drugs
4-thio-2-deoxycytidine
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02423057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02423057.